Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 2/20 | 0.61 |
| ▸ | NR4A2 | P43354 | 4/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.52 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.51 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.49 |
| ▸ | CTSV | O60911 | 1/20 | 0.49 |
| ▸ | CTSL | P07711 | 1/20 | 0.49 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.48 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1368181 | 0.87 | TP53 (0.63) | NR4A2NPC1RAB9ATP53HTT | |
| SCHEMBL1756444 | 0.86 | MRGPRX4 (0.63) | NR4A2NPC1RAB9ATP53HTT | |
| SCHEMBL4215754 | 0.86 | NR4A2 (0.59) | HIF1ANR4A2NPC1RAB9ATP53 | |
| SCHEMBL14417302 | 0.86 | HIF1A (0.63) | HIF1ANR4A2NPC1RAB9ACYP3A4 | |
| SCHEMBL11572828 | 0.85 | MRGPRX4 (0.64) | HIF1ANR4A2NPC1RAB9ATP53 | |
| SCHEMBL490469 | 0.85 | MRGPRX4 (0.62) | HIF1ANR4A2NPC1RAB9ATP53 | |
| SCHEMBL11618784 | 0.84 | NR4A2 (0.53) | HIF1ANR4A2NPC1RAB9ATP53 | |
| SCHEMBL2557002 | 0.82 | NPC1 (0.63) | HIF1ANR4A2NPC1RAB9ATP53 | |
| SCHEMBL11618778 | 0.82 | CFD (0.55) | HIF1ANR4A2NPC1RAB9ATP53 | |
| SCHEMBL11600649 | 0.81 | MRGPRX4 (0.61) | NR4A2NPC1RAB9ATP53HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582794-B2 | Process for the preparation of substituted 2-(phenoxymethyl)benzoic acids | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-09-01 | — | — | US | disclosed |
| US-7582794-B2 | Process for the preparation of substituted 2-(phenoxymethyl)benzoic acids | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-09-01 | — | — | US | disclosed |
| EP-1699748-B1 | METHOD FOR THE PRODUCTION OF SUBSTITUTED 2-(PHENOXYMETHYL)-BENZOIC ACIDS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-10-15 | — | — | EP | disclosed |
| US-20070219395-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED 2-(PHENOXYMETHYL)BENZOIC ACIDS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-09-20 | — | — | US | disclosed |
| US-20070219395-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED 2-(PHENOXYMETHYL)BENZOIC ACIDS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-09-20 | — | — | US | disclosed |
| US-7238835-B2 | Process for the preparation of substituted 2-(phenoxymethyl) benzoic acids | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-07-03 | — | — | US | disclosed |
| US-7238835-B2 | Process for the preparation of substituted 2-(phenoxymethyl) benzoic acids | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-07-03 | — | — | US | disclosed |
| CN-1898190-A | Process for producing substituted 2- (phenoxymethyl) benzoic acid | AVENTIS PHARMA GMBH (DE) | 2007-01-17 | — | — | CN | disclosed |
| EP-1699748-A2 | METHOD FOR THE PRODUCTION OF SUBSTITUTED 2-(PHENOXYMETHYL)-BENZOIC ACIDS | Sanofi-Aventis Deutschland GmbH (DE) | 2006-09-13 | — | — | EP | disclosed |
| US-20050171205-A1 | Process for the preparation of substituted 2-(phenoxymethyl) benzoic acids | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-08-04 | — | — | US | disclosed |
| WO-2005061427-A2 | METHOD FOR THE PRODUCTION OF SUBSTITUTED 2-(PHENOXYMETHYL)-BENZOIC ACIDS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219395-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED 2-(PHENOXYMETHYL)BENZOIC ACIDS | CYP2B6, CYP1B1, CYP4B1 | HIF1A 672/4885NR4A2 2506/4885NPC1 3120/4885 |
| US-20050171205-A1 | Process for the preparation of substituted 2-(phenoxymethyl) benzoic acids | CYP2B6, CYP1B1, CYP4B1 | HIF1A 672/4885NR4A2 2506/4885NPC1 3120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.